Synopsis of a clinical practice guideline for pancreatic ductal adenocarcinoma with peritoneal dissemination in Japan; Japan Peritoneal Malignancy Study Group. (7th January 2022)
- Record Type:
- Journal Article
- Title:
- Synopsis of a clinical practice guideline for pancreatic ductal adenocarcinoma with peritoneal dissemination in Japan; Japan Peritoneal Malignancy Study Group. (7th January 2022)
- Main Title:
- Synopsis of a clinical practice guideline for pancreatic ductal adenocarcinoma with peritoneal dissemination in Japan; Japan Peritoneal Malignancy Study Group
- Authors:
- Satoi, Sohei
Takahara, Naminatsu
Fujii, Tsutomu
Isayama, Hiroyuki
Yamada, Suguru
Tsuji, Yasushi
Miyato, Hideyo
Yamaguchi, Hironori
Yamamoto, Tomohisa
Hashimoto, Daisuke
Yamaki, So
Nakai, Yousuke
Saito, Kei
Baba, Hayato
Watanabe, Toru
Ishii, Shigeto
Hayashi, Masamichi
Kurimoto, Keisuke
Shimada, Hideaki
Kitayama, Joji - Abstract:
- Abstract: Patients with pancreatic ductal adenocarcinoma (PDAC) with peritoneal dissemination have a dismal prognosis because discontinuation of systemic chemotherapy is required for massive ascites or poor performance status. The natural history, diagnosis and treatment of PDAC with peritoneal dissemination have not been fully investigated. We systematically reviewed published information on the clinical diagnosis and treatment of PDAC with peritoneal dissemination using the PubMed database (2000‐2020) and provided recommendations in response to clinical questions. This guideline was created according to the "Minds Clinical Practice Guideline Development Guide 2017". The literature quality and body of evidence were evaluated with the GRADE System and classified into four levels ("strong", "medium", "weak", "very weak"). The strength of each final recommendation was decided by a vote of committee members based on the GRADE Grid method. These guidelines address three subjects: diagnostic, chemotherapeutic, and surgical approaches. They include nine clinical questions and statements with recommendation strengths, evidence levels, and agreement rates, in addition to one "column". This is the English synopsis of the 2021 Japanese clinical practice guideline for PDAC with peritoneal dissemination. It summarizes the clinical evidence for the diagnosis and treatment of PDAC with peritoneal dissemination and provides future perspectives. Abstract : Highlight On behalf of the JapanAbstract: Patients with pancreatic ductal adenocarcinoma (PDAC) with peritoneal dissemination have a dismal prognosis because discontinuation of systemic chemotherapy is required for massive ascites or poor performance status. The natural history, diagnosis and treatment of PDAC with peritoneal dissemination have not been fully investigated. We systematically reviewed published information on the clinical diagnosis and treatment of PDAC with peritoneal dissemination using the PubMed database (2000‐2020) and provided recommendations in response to clinical questions. This guideline was created according to the "Minds Clinical Practice Guideline Development Guide 2017". The literature quality and body of evidence were evaluated with the GRADE System and classified into four levels ("strong", "medium", "weak", "very weak"). The strength of each final recommendation was decided by a vote of committee members based on the GRADE Grid method. These guidelines address three subjects: diagnostic, chemotherapeutic, and surgical approaches. They include nine clinical questions and statements with recommendation strengths, evidence levels, and agreement rates, in addition to one "column". This is the English synopsis of the 2021 Japanese clinical practice guideline for PDAC with peritoneal dissemination. It summarizes the clinical evidence for the diagnosis and treatment of PDAC with peritoneal dissemination and provides future perspectives. Abstract : Highlight On behalf of the Japan Peritoneal Malignancy Study Group, Satoi and colleagues present an English synopsis of the 2021 Japanese clinical practice guidelines for pancreatic ductal adenocarcinoma with peritoneal dissemination. It summarizes the clinical evidence for the diagnosis and treatment of pancreatic ductal adenocarcinoma with peritoneal dissemination and provides future perspectives. … (more)
- Is Part Of:
- Journal of hepato-biliary-pancreatic sciences. Volume 29:Number 6(2022)
- Journal:
- Journal of hepato-biliary-pancreatic sciences
- Issue:
- Volume 29:Number 6(2022)
- Issue Display:
- Volume 29, Issue 6 (2022)
- Year:
- 2022
- Volume:
- 29
- Issue:
- 6
- Issue Sort Value:
- 2022-0029-0006-0000
- Page Start:
- 600
- Page End:
- 608
- Publication Date:
- 2022-01-07
- Subjects:
- guideline -- pancreatic ductal adenocarcinoma -- peritoneal dissemination
Liver -- Diseases -- Periodicals
Biliary tract -- Diseases -- Periodicals
Pancreas -- Diseases -- Periodicals
617.556 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1868-6982 ↗
http://www.springerlink.com/content/121581 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/jhbp.1085 ↗
- Languages:
- English
- ISSNs:
- 1868-6974
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4997.660000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 22286.xml